Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

33.76 +1.48 (+4.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 699,875
Open 31.58
Bid (Size) 33.75 (1)
Ask (Size) 33.76 (159)
Prev. Close 32.28
Today's Range 31.45 - 33.76
52wk Range 27.36 - 56.00
Shares Outstanding 59,066,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... 
Via FinancialNewsMedia
Sage Therapeutics to Present at Upcoming June Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire

Performance

YTD
-22.55%
-22.55%
1 Month
-8.46%
-8.46%
3 Month
-11.13%
-11.13%
6 Month
-22.55%
-22.55%
1 Year
-38.24%
-38.24%

More News

Read More
Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same
Via Investor's Business Daily
8 Analysts Have This to Say About Sage Therapeutics
Via Benzinga
Sage Therapeutics: Q1 Earnings Insights
Via Benzinga
Expert Ratings For Sage Therapeutics
Via Benzinga
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
From Sage Therapeutics, Inc.
Via Business Wire
Analyst Ratings for Sage Therapeutics
Via Benzinga
Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
Earnings Scheduled For May 3, 2022
Via Benzinga
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
From Sage Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Via Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
Via Benzinga
Sage Therapeutics to Present at 2022 Stifel CNS Days
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Expert Ratings For Sage Therapeutics
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.